Literature DB >> 33020169

Pregnancy protection and pregnancies in women prescribed ACE inhibitors or ARBs: a cross-sectional study in primary care.

Elizabeth Lovegrove1, John Robson2, Patricia McGettigan2.   

Abstract

BACKGROUND: The teratogenic risks of angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are well documented, but prescribing these in younger women in primary care is becoming increasingly frequent. AIM: To record how frequently women of childbearing age, who are prescribed an ACE inhibitor or ARB, receive preconception advice and/or are prescribed contraception, and how many pregnancies, terminations, and miscarriages occur in this population. Additionally, to ascertain whether patterns in the above differ across age groups. DESIGN AND
SETTING: Cross-sectional study conducted among patients from 141 general practices in East London.
METHOD: Women aged 15-45 years who were issued a prescription for an ACE inhibitor or ARB between 1 October 2018 and 1 January 2019 inclusive were included. An electronic search strategy was designed to extract pseudonymised data concerning preconception and contraception advice, contraception, and pregnancies from the electronic clinical system; this was applied to the selected cohort on 1 January 2019. Data were analysed in 5-year age groups.
RESULTS: Of 302 939 women aged 15-45 years, 2651 (0.9%) were prescribed an ACE inhibitor or an ARB in a 3-month period. Of these, 2159 (81.4%) had no advice and no contraception prescription recorded, 35 (1.3%) had preconception advice recorded, and 230 (8.7%) had contraception advice recorded. A total of 100 pregnancies and 21 terminations/miscarriages were recorded in the 12 months preceding the index date (1 January 2019).
CONCLUSION: This study found that the recording of pre-pregnancy advice and contraception in women of childbearing age who were prescribed an ACE inhibitor or an ARB was suboptimal; this may place women and their babies at risk of exposure to teratogens during pregnancy. The findings indicate that there is a need for improved safety strategies based in primary care. © British Journal of General Practice 2020.

Entities:  

Keywords:  angiotensin receptor blockers; angiotensin-converting enzyme inhibitors; contraception; female; pregnancy; primary health care

Mesh:

Substances:

Year:  2020        PMID: 33020169      PMCID: PMC7537996          DOI: 10.3399/bjgp20X712997

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  26 in total

1.  Teratogen use in women of childbearing potential: an intervention study.

Authors:  Karie A Morrical-Kline; Alison M Walton; Tracey M Guildenbecher
Journal:  J Am Board Fam Med       Date:  2011 May-Jun       Impact factor: 2.657

2.  Major congenital malformations after first-trimester exposure to ACE inhibitors.

Authors:  William O Cooper; Sonia Hernandez-Diaz; Patrick G Arbogast; Judith A Dudley; Shannon Dyer; Patricia S Gideon; Kathi Hall; Wayne A Ray
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

Review 3.  Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review.

Authors:  Marina Bullo; Sibylle Tschumi; Barbara S Bucher; Mario G Bianchetti; Giacomo D Simonetti
Journal:  Hypertension       Date:  2012-07-02       Impact factor: 10.190

4.  Perspectives of primary care clinicians on teratogenic risk counseling.

Authors:  Eleanor Bimla Schwarz; Aimee Santucci; Sonya Borrero; Aletha Y Akers; Cara Nikolajski; Melanie A Gold
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2009-10

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Increasing exposure to angiotensin-converting enzyme inhibitors in pregnancy.

Authors:  Michael E Bowen; Wayne A Ray; Patrick G Arbogast; Hua Ding; William O Cooper
Journal:  Am J Obstet Gynecol       Date:  2008-01-14       Impact factor: 8.661

7.  The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers.

Authors:  Myla E Moretti; Daniela Caprara; Irina Drehuta; Emily Yeung; Stefanie Cheung; Lisa Federico; Gideon Koren
Journal:  Obstet Gynecol Int       Date:  2011-12-13

8.  The prevalence of unplanned pregnancy and associated factors in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3).

Authors:  Kaye Wellings; Kyle G Jones; Catherine H Mercer; Clare Tanton; Soazig Clifton; Jessica Datta; Andrew J Copas; Bob Erens; Lorna J Gibson; Wendy Macdowall; Pam Sonnenberg; Andrew Phelps; Anne M Johnson
Journal:  Lancet       Date:  2013-11-26       Impact factor: 79.321

Review 9.  The Global Epidemic of the Metabolic Syndrome.

Authors:  Mohammad G Saklayen
Journal:  Curr Hypertens Rep       Date:  2018-02-26       Impact factor: 5.369

10.  Health indicator recording in UK primary care electronic health records: key implications for handling missing data.

Authors:  Irene Petersen; Catherine A Welch; Irwin Nazareth; Kate Walters; Louise Marston; Richard W Morris; James R Carpenter; Tim P Morris; Tra My Pham
Journal:  Clin Epidemiol       Date:  2019-02-11       Impact factor: 4.790

View more
  3 in total

1.  First do no harm: valproate and medicines safety in pregnancy.

Authors:  John Robson; Ngawai Moss; Patricia McGettigan; Samantha Jane Beardsley; Elizabeth Lovegrove; Carol Dezateux
Journal:  Br J Gen Pract       Date:  2020-10-01       Impact factor: 5.386

2.  A Case of a Pregnant Woman With Primary Aldosteronism and Superimposed Preeclampsia Treated With Esaxerenone.

Authors:  Kaoru Yamashita; Satoshi Morimoto; Yuko Inoue; Kiyotaka Hirata; Shihori Kimura; Yasufumi Seki; Kanako Bokuda; Daisuke Watanabe; Atsuhiro Ichihara
Journal:  J Endocr Soc       Date:  2022-05-29

Review 3.  Sex differences in hypertension. Do we need a sex-specific guideline?

Authors:  Renata Cífková; Larysa Strilchuk
Journal:  Front Cardiovasc Med       Date:  2022-08-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.